Literature DB >> 27604397

Pepsin in saliva as a biomarker for oropharyngeal reflux compared with 24-hour esophageal impedance/pH monitoring in pediatric patients.

J E Fortunato1, R B D'Agostino2, M O Lively3.   

Abstract

BACKGROUND: Pepsin in saliva is a proposed biomarker for oropharyngeal reflux. Pepsin may be prevalent in saliva from subjects with gastro-esophageal reflux and may correlate with proximal reflux by intraluminal impedance/pH monitoring (MII/pH).
METHODS: Patients (3 days to 17.6 years, n=90) undergoing 24-hour MII/pH monitoring and asymptomatic controls (2 months to 13.7 years, n=43) were included. Salivary pepsin was determined using a pepsin enzyme-linked immunosorbent assay. Eight saliva samples were collected from patients undergoing 24-hr MII/pH: (i) before catheter placement, (ii) before and 30 minutes after each of three meals, and (iii) upon awakening. One sample was collected from each control. KEY
RESULTS: In MII/pH subjects, 85.6% (77/90) had at least one pepsin-positive sample compared with 9.3% (4/43) in controls. The range of pepsin observed in individual subjects varied widely over 24 hours. The average pepsin concentration in all samples obtained within 2 hours following the most recent reflux event was 30.7±135 ng/mL, decreasing to 16.5±39.1 ng/mL in samples collected more than 2 hours later. The frequency of pepsin-positive samples correlated significantly with symptom index (rS =0.332, P=.0014), proximal (rS =0.340, P=.0010), and distal (rS =0.272, P=.0095) MII events. CONCLUSIONS & INFERENCES: Concentration of salivary pepsin may not be an accurate measure of severity of reflux because of the wide range observed in individuals over 24 hours. Saliva samples must be obtained soon after a reflux event. Defining a regimen for optimal saliva collection may help to achieve the goal of using salivary pepsin as a biomarker for oropharyngeal reflux. CLINICAL TRIAL REGISTRY: NCT01091805.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  gastro-esophageal reflux; multichannel intraluminal impedance/pH monitoring; oropharyngeal pepsin; oropharyngeal reflux; pepsin; saliva

Mesh:

Substances:

Year:  2016        PMID: 27604397     DOI: 10.1111/nmo.12936

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Pepsin in saliva as a diagnostic biomarker in laryngopharyngeal reflux: a meta-analysis.

Authors:  Jing Wang; Yu Zhao; Jianjun Ren; Yang Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-13       Impact factor: 2.503

2.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

3.  The diagnostic value of pepsin detection in saliva for gastro-esophageal reflux disease: a preliminary study from China.

Authors:  Xing Du; Feng Wang; Zhiwei Hu; Jimin Wu; Zhonggao Wang; Chao Yan; Chao Zhang; Juan Tang
Journal:  BMC Gastroenterol       Date:  2017-10-17       Impact factor: 3.067

4.  Label-Free Detection of Salivary Pepsin Using Gold Nanoparticle/Polypyrrole Nanocoral Modified Screen-Printed Electrode.

Authors:  Doyeon Lee; Young Ju Lee; Young-Gyu Eun; Gi-Ja Lee
Journal:  Sensors (Basel)       Date:  2018-05-24       Impact factor: 3.576

Review 5.  Pepsin and Laryngeal and Hypopharyngeal Carcinomas.

Authors:  Cheng-Yi Yin; Sha-Sha Zhang; Jiang-Tao Zhong; Shui-Hong Zhou
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-07-24       Impact factor: 3.372

6.  Pepsin as a Marker of Reflux Aspiration in Children With Esophageal Atresia: A Pilot Study.

Authors:  Yadhavan Upendran; Steven T Leach; Harveen Singh; James McBride; Paul S Thomas; Yvonne Belessis; Usha Krishnan
Journal:  Front Pediatr       Date:  2020-03-19       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.